TLDR
- Tempus AI (TEM) stock reached an all-time high of $98.14 and closed at $103.25, up 11.01% on Wednesday
- The company has gained 205.84% year-to-date in 2025 and 114.75% over the past year
- Ryan Fukushima’s spouse sold 5,000 shares worth $461,605 under a pre-arranged trading plan on October 6
- Former House Speaker Nancy Pelosi’s January call options investment in Tempus AI is now worth approximately $415,000
- Tempus AI received FDA 510(k) clearance for its RNA-based Tempus xR IVD device and updated Tempus Pixel cardiac imaging platform
Tempus AI closed at $103.25 on Wednesday, marking an 11.01% gain during regular trading hours. The stock reached an intraday all-time high of $98.14 before settling above the $100 mark.
The Chicago-based health technology company has posted a 205.84% gain year-to-date in 2025. Over the past twelve months, shares have climbed 114.75%.
The company’s market capitalization now stands at $17.94 billion. Tempus AI’s share price has traded in a range between $31.36 and $103.42 during the current period.
Analysts have set price targets ranging from $60 to $100 for the stock. InvestingPro data shows the company reported revenue growth of 59.84% over the last twelve months.
FDA Clearances and Product Updates
Tempus AI received 510(k) clearance from the FDA for its RNA-based Tempus xR IVD device. The device will be used as a life sciences tool to support drug development programs by detecting gene rearrangements in tumor tissues.
The company also received clearance for an updated version of Tempus Pixel. This AI-driven cardiac imaging platform represents another expansion of the company’s diagnostic capabilities.
Tempus AI updated its CARE Program by incorporating breast density into the Tyrer-Cuzick breast cancer risk assessment model. The update aims to improve screening recommendations for at-risk patients.
Analyst Upgrades and Price Targets
Guggenheim raised its price target for Tempus AI to $95 while maintaining a Buy rating. The firm cited discussions about the company’s oncology AI model development.
H.C. Wainwright increased its price target to $98. The upgrade followed the FDA clearance of the updated Tempus Pixel platform.
InvestingPro analysis assigned the stock a “GOOD” overall financial health score. The analysis noted the company’s strong market position in the artificial intelligence sector.
Insider Trading Activity
On October 6, the spouse of Chief Operating Officer Ryan Fukushima sold 5,000 shares worth $461,605.58. The sales were executed under a pre-arranged trading plan established on March 4.
SEC filings show the shares were sold at average prices between $90.84 and $92.96. Following the sales, Fukushima’s spouse retained 130,000 shares as indirect holdings.
Fukushima directly owns 839,180 shares. He holds an additional 131,893 shares through the Ryan Fukushima Irrevocable Family Trust.
Congressional Interest
Former House Speaker Nancy Pelosi purchased call options in Tempus AI during January. Her initial investment ranged between $50,000 and $100,000.
The options position is now valued at approximately $415,000. This represents a gain of over 300% from the original investment cost.
Trading Metrics
The stock added 0.20% in after-hours trading on Wednesday to reach $103.46. Average daily trading volume stands at 8.56 million shares.
Benzinga’s Edge Stock Rankings placed Tempus AI’s momentum in the 93rd percentile. The rankings indicate a positive price trend across all measured time frames.
Stay Ahead of the Market with Benzinga Pro!
Want to trade like a pro? Benzinga Pro gives you the edge you need in today's fast-paced markets. Get real-time news, exclusive insights, and powerful tools trusted by professional traders:
- Breaking market-moving stories before they hit mainstream media
- Live audio squawk for hands-free market updates
- Advanced stock scanner to spot promising trades
- Expert trade ideas and on-demand support
